Novo Nordisk A/S (NYSE:NVO) Cut to Hold at Hsbc Global Res

Novo Nordisk A/S (NYSE:NVO) was downgraded by equities research analysts at Hsbc Global Res from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities analysts have also issued reports on the company. Morgan Stanley cut Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their price target for the company from $59.00 to $47.00 in a research report on Monday, September 29th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. UBS Group downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $44.99 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $112.52. The firm has a market cap of $200.88 billion, a PE ratio of 12.36, a PEG ratio of 2.33 and a beta of 0.65. The firm has a fifty day moving average of $53.71 and a 200 day moving average of $60.14.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.74 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

A number of large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the period. Kingstone Capital Partners Texas LLC lifted its holdings in shares of Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares in the last quarter. Capital International Investors grew its stake in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth about $310,199,000. Finally, Nuveen LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $370,272,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.